Current role
Matthew Henn, Ph.D.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Matthew Henn, Ph.D.
Seres Therapeutics, Inc. reported in an 8-K filed March 2, 2026 that Matthew Henn, Ph.D. was appointed President and Chief Scientific Officer, effective March 2, 2026.
“Commencing on the Effective Date, you will serve as the Company’s President and Chief Scientific Officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Seres Therapeutics, Inc. (MCRB)
SEC 8-K
Current2026-03-02–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Seres Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Marella Thorell CEO, CFO, Chief Accounting Officer
- Richard N. Kender CEO, Chairman, Board Member
- Roger J. Pomerantz CEO
- Kelly Brady COO
- Kelly Brady, M.S. COO
- David S. Ege CTO
- David Arkowitz Chief Accounting Officer
- Eric Shaff Chief Accounting Officer
- Claire Fraser, Ph.D. Board Member
- Claire M. Fraser, Ph.D. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.